Cargando…
Defining the Efficacy and Safety of Phosphodiesterase Type 5 Inhibitors with Tamsulosin for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia with or without Erectile Dysfunction: A Network Meta-Analysis
PURPOSE: The purpose of this study was to compare the relative safety and efficacy of different types of phosphodiesterase type 5 inhibitors (PDE5-Is) with tamsulosin for the treatment of lower urinary tract symptoms (LUTS) secondary to benign prostate hyperplasia (BPH) (BPH-LUTS) with or without er...
Autores principales: | Ma, Chengquan, Zhang, Jianzhong, Cai, Zhonglin, Xiong, Jian, Li, Hongjun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7140123/ https://www.ncbi.nlm.nih.gov/pubmed/32309423 http://dx.doi.org/10.1155/2020/1419520 |
Ejemplares similares
-
To evaluate the efficacy and safety of different kinds of PDE5-Is with tamsulosin as a medical therapy for LUTS secondary to benign prostatic hyperplasia: A protocol for systematic review and meta analysis
por: Ma, Chengquan, et al.
Publicado: (2020) -
Impact of Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia Treatment with Tamsulosin and Solifenacin Combination Therapy on Erectile Function
por: Seo, Deok Ha, et al.
Publicado: (2011) -
Phosphodiesterase type 5 inhibitors for treating erectile dysfunction and lower urinary tract symptoms secondary to benign prostatic hyperplasia: A comprehensive review
por: Haddad, Albert, et al.
Publicado: (2015) -
Comparative evaluation of naftopidil and tamsulosin in the treatment of patients with lower urinary tract symptoms with benign prostatic hyperplasia
por: Griwan, Mahavir Singh, et al.
Publicado: (2014) -
Tadalafil vs. tamsulosin in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: a prospective, randomized study
por: Pogula, Vedamurthy Reddy, et al.
Publicado: (2019)